Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
Michael Kors Marks 45 Years at New York Fashion Week with Fall/Winter Collection Showcase 
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute 
Converse Cuts Corporate Jobs as Nike Restructures to Revive Sales Growth 
Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal 
Lyft Shares Slide After Weak Q1 Profit Forecast and Surprise 2025 Operating Loss 
FTC Questions Apple News Over Alleged Bias Against Conservative Media 
Westpac (ASX: WBC) Q1 Profit Rises 6% as Lending Growth and Treasury Income Strengthen Earnings 
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
Spirit Airlines Seeks Court Approval to Auction 20 Airbus A320/A321 Aircraft Amid Bankruptcy 
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
EDISON, N.J., Jan. 02, 2018 -- ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that it will present at the Biotech Showcase Conference 2018 to be held January 8-10, 2018 at the Hilton San Francisco Union Square.
James Sapirstein, Chief Executive Officer of ContraVir, will provide an overview on the company’s business during his presentation and will be available to participate in one-on-one meetings with investors who are registered to attend the conference.
Presentation details are as follows:
| Event | Biotech Showcase 2018 |
| Date | Monday, January 8, 2018 |
| Time | 2:00PM |
| Location | Yosemite - C (Ballroom Level) |
About ContraVir Pharmaceuticals
ContraVir is a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies with a specific focus on developing a potentially curative therapy for hepatitis B virus (HBV). The Company is developing two novel anti-HBV compounds with complementary mechanisms of action. TXL™, designed to deliver high intrahepatic concentrations of TFV while minimizing off-target effects caused by high levels of circulating TFV, recently completed a Phase 2a trial. CRV431, the other anti-HBV compound, is a next-generation cyclophilin inhibitor with a unique structure that increases its potency and selective index against HBV. In vitro and in vivo studies have thus far demonstrated that CRV431 reduces HBV DNA and other viral proteins, including surface antigen (HBsAg). For more information visit www.contravir.com.
For further information, please contact:
Sharen Pyatetskaya
Director of Investor Relations
[email protected]; (732) 902-4028
